A phase I randomized placebo controlled trial of the safety of 3% SPL7013 Gel (VivaGel®) in healthy young women administered twice daily for 14 days.

To assess the safety of VivaGel® used vaginally twice daily for 14 days among healthy, sexually-abstinent women, aged 18-24 years in the USA and Kenya.Randomized placebo controlled trial.Participants were randomized 2∶1, VivaGel to placebo. Safety was assessed by comparing genitourinary (GU) adverse...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Craig R Cohen, Joelle Brown, Anna-Barbara Moscicki, Elizabeth A Bukusi, Jeremy R A Paull, Clare F Price, Stephen Shiboski
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Public Library of Science (PLoS) 2011-01-01
Edice:	PLoS ONE
On-line přístup:	http://europepmc.org/articles/PMC3024437?pdf=render
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!